Many patients with systemic autoimmune rheumatic diseases (SARDs) require immunosuppression to reduce disease activity, but this also has important possible detrimental impacts on immune responses following vaccination. The phase III clinical trials for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines did not include those who are immunosuppressed. Fortunately, we now have a clearer idea of how immune responses following SARS-CoV-2 vaccination has for the immunosuppressed, with much of the data being within a year of its introduction. Here, we summarize what is known in this rapidly evolving field about the impact immunosuppression has on humoral immunogenicity including waning immunity and additional doses, breakthrough infection rates and severity, disease flare rates, along with additional considerations and remaining unanswered questions.

许多患有全身性自身免疫性风湿病 (SARD) 的患者需要免疫抑制来降低疾病活动度，但这也可能对接种疫苗后的免疫反应产生重要的不利影响。严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 疫苗的 III 期临床试验不包括那些免疫抑制的人。幸运的是，我们现在更清楚地了解 SARS-CoV-2 疫苗接种后的免疫反应如何对免疫抑制者产生影响，其中大部分数据是在其引入后一年内获得的。在这里，我们总结了这个快速发展的领域中已知的关于免疫抑制对体液免疫原性的影响，包括免疫力减弱和额外剂量、突破性感染率和严重程度、疾病发作率、